Calendario›AMGN›AMG 706

AMG 706

Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors

Ensayo de AMGEN INC en Tumor solido avanzado.

Más ensayos de: Tumor sólido avanzado.

Fase

Fase 1

Estado

Completado

Participantes

4

previstos

Fin del objetivo primario

nov 2010

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en may 2009.

Qué mide

Profile and identification of metabolites of [14C]-AMG 706 in plasma, urine, and faeces (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroIn order for a tumour to grow and spread to other parts of the body, it needs to have a blood supply. Certain proteins in the body, called cytokines or growth factors, have been shown to cause the growth of new blood vessels that supply tumours and therefore help the tumour to grow and spread. Motesanib (AMG 706) prevents these proteins from working, and may help to prevent the growth of tumours. In the first part of this study, we will look at the way your body absorbs this drug into your blood, how your body changes and breaks down the drug, and then how the drug leaves your body in your urine and faeces. In order to provide potential treatment benefit for the subjects who participated in the first part of the study, the second part of the study will allow subjects to continue on motesanib (AMG 706) treatment. The estimated length of this part of the study is unknown, and dependent on how subjects respond to motesanib (AMG 706).

Más ensayos de AMGN

Todos los de AMGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01386866), actualizada en jul 2011.